View Cart  

Abbott Hits Watson With Second Suit Against Expanded Niaspan ANDA

A A
Abbott is continuing to put legal pressure on Watson now that the generic-drug maker has expanded its Niaspan ANDA to include the 750-mg version of Abbott’s billion-dollar cholesterol treatment.

To View This Article:

Login

Subscribe To Drug Industry Daily